{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SC&page=41", "query": { "intervention": "SC", "page": 41 }, "page_size": 10 }, "pagination": { "page": 41, "page_size": 10, "total_count": 3862, "total_pages": 387, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SC&page=42&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SC&page=40&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-31T08:30:26.756Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01844518", "title": "Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents With Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Inadequate Response (IR) to Biologic or Non Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Active Polyarticular Juvenile Idiopathic Arthritis" ], "interventions": [ { "name": "Abatacept", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "2 Years to 17 Years" }, "enrollment_count": 219, "start_date": "2013-08-30", "completion_date": "2023-02-01", "has_results": true, "last_update_posted_date": "2023-07-12", "last_synced_at": "2026-10-31T08:30:26.756Z", "location_count": 12, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Hartford, Connecticut + 9 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01844518" }, { "nct_id": "NCT02876835", "title": "Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anaemia" ], "interventions": [ { "name": "Daprodustat", "type": "DRUG" }, { "name": "Darbepoetin alfa", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Iron Therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 3872, "start_date": "2016-09-27", "completion_date": "2021-04-19", "has_results": true, "last_update_posted_date": "2024-04-02", "last_synced_at": "2026-10-31T08:30:26.756Z", "location_count": 161, "location_summary": "Andalusia, Alabama • Birmingham, Alabama • Huntsville, Alabama + 128 more", "locations": [ { "city": "Andalusia", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02876835" }, { "nct_id": "NCT04148118", "title": "A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Anthrax Vaccine in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anthrax" ], "interventions": [ { "name": "BW-1010: 50 µg - sprayer - IN", "type": "BIOLOGICAL" }, { "name": "BW-1010: 50 µg - pipette - IN", "type": "BIOLOGICAL" }, { "name": "BW-1010: 100 µg - sprayer - IN", "type": "BIOLOGICAL" }, { "name": "BW-1010: 100 µg - pipette - IN", "type": "BIOLOGICAL" }, { "name": "Saline (Placebo) - sprayer - IN", "type": "BIOLOGICAL" }, { "name": "Saline (Placebo) - pipette - IN", "type": "BIOLOGICAL" }, { "name": "BioThrax (positive control) - SC", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "BlueWillow Biologics", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "ALL", "summary": "18 Years to 49 Years" }, "enrollment_count": 84, "start_date": "2020-01-08", "completion_date": "2021-09-02", "has_results": false, "last_update_posted_date": "2022-05-18", "last_synced_at": "2026-10-31T08:30:26.756Z", "location_count": 1, "location_summary": "Lenexa, Kansas", "locations": [ { "city": "Lenexa", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04148118" }, { "nct_id": "NCT03438318", "title": "Study Evaluating CMP-001 in Combination With Atezolizumab in Participants With Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "CMP-001", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2018-03-15", "completion_date": "2019-12-11", "has_results": false, "last_update_posted_date": "2022-08-03", "last_synced_at": "2026-10-31T08:30:26.756Z", "location_count": 5, "location_summary": "Gilbert, Arizona • Duarte, California • Aurora, Colorado + 2 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03438318" }, { "nct_id": "NCT03621774", "title": "Mobile CBT for Negative Symptoms", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Schizophrenia", "Schizoaffective Disorder" ], "interventions": [ { "name": "Mobile-assisted CBT-informed Skills Training", "type": "BEHAVIORAL" }, { "name": "Supportive Contact", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of California, San Diego", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 112, "start_date": "2019-03-27", "completion_date": "2022-08-31", "has_results": false, "last_update_posted_date": "2024-11-08", "last_synced_at": "2026-10-31T08:30:26.756Z", "location_count": 1, "location_summary": "La Jolla, California", "locations": [ { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03621774" }, { "nct_id": "NCT02650635", "title": "TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Adenocarcinoma", "Metastatic Pancreatic Adenocarcinoma", "Recurrent Breast Carcinoma", "Recurrent Colorectal Carcinoma", "Recurrent Melanoma of the Skin", "Recurrent Non-Small Cell Lung Carcinoma", "Recurrent Pancreatic Carcinoma", "Recurrent Renal Cell Carcinoma", "Solid Neoplasm", "Stage IV Breast Cancer", "Stage IV Non-Small Cell Lung Cancer", "Stage IV Renal Cell Cancer", "Stage IV Skin Melanoma", "Stage IVA Colorectal Cancer", "Stage IVA Pancreatic Cancer", "Stage IVB Colorectal Cancer", "Stage IVB Pancreatic Cancer" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pegfilgrastim", "type": "BIOLOGICAL" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "TLR8 Agonist VTX-2337", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2016-02-05", "completion_date": "2017-06-01", "has_results": false, "last_update_posted_date": "2018-09-05", "last_synced_at": "2026-10-31T08:30:26.756Z", "location_count": 1, "location_summary": "Scottsdale, Arizona", "locations": [ { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02650635" }, { "nct_id": "NCT01049035", "title": "A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Meningitis", "Meningococcal Infection" ], "interventions": [ { "name": "Quadrivalent Meningococcal Polysaccharide (A, C, Y, and W-135) Tetanus Protein Conjugate", "type": "BIOLOGICAL" }, { "name": "Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus B Conjugate (Tetanus Toxoid Conjugate) Vaccine Combined (DTaP-IPV/Hib combined)", "type": "BIOLOGICAL" }, { "name": "M-M-RII-Measles, Mumps, and Rubella Virus Vaccine Live", "type": "BIOLOGICAL" }, { "name": "Varicella Virus Vaccine Live", "type": "BIOLOGICAL" }, { "name": "Pneumococcal 7-valent Conjugate Vaccine (Diphtheria CRM197 Protein)", "type": "BIOLOGICAL" }, { "name": "Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein)", "type": "BIOLOGICAL" }, { "name": "Rotavirus Vaccine", "type": "BIOLOGICAL" }, { "name": "Hepatitis B Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Sanofi Pasteur, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "42 Days", "maximum_age": "365 Days", "sex": "ALL", "summary": "42 Days to 365 Days" }, "enrollment_count": 580, "start_date": "2009-12-16", "completion_date": "2012-02-13", "has_results": true, "last_update_posted_date": "2022-03-28", "last_synced_at": "2026-10-31T08:30:26.756Z", "location_count": 25, "location_summary": "Birmingham, Alabama • Tuscaloosa, Alabama • Jonesboro, Arkansas + 20 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Fountain Valley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01049035" }, { "nct_id": "NCT05578976", "title": "A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Epcoritamab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genmab", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "79 Years", "sex": "ALL", "summary": "18 Years to 79 Years" }, "enrollment_count": 900, "start_date": "2023-02-08", "completion_date": "2029-12", "has_results": false, "last_update_posted_date": "2026-09-11", "last_synced_at": "2026-10-31T08:30:26.756Z", "location_count": 68, "location_summary": "Tucson, Arizona • Yuma, Arizona • Little Rock, Arkansas + 57 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Yuma", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Bakersfield", "state": "California" }, { "city": "Berkeley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05578976" }, { "nct_id": "NCT07157787", "title": "Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Primary Membranous Nephropathy" ], "interventions": [ { "name": "ALXN1920", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alexion Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 30, "start_date": "2025-09-19", "completion_date": "2027-07-09", "has_results": false, "last_update_posted_date": "2026-06-18", "last_synced_at": "2026-10-31T08:30:26.756Z", "location_count": 5, "location_summary": "Loma Linda, California • San Diego, California • Minneapolis, Minnesota + 2 more", "locations": [ { "city": "Loma Linda", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07157787" }, { "nct_id": "NCT07540221", "title": "A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)" ], "interventions": [ { "name": "Gamunex-C", "type": "BIOLOGICAL" }, { "name": "Xembify", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Grifols Therapeutics LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2026-04-02", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-10-09", "last_synced_at": "2026-10-31T08:30:26.756Z", "location_count": 9, "location_summary": "Rancho Mirage, California • Coral Springs, Florida • Miami, Florida + 6 more", "locations": [ { "city": "Rancho Mirage", "state": "California" }, { "city": "Coral Springs", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Port Charlotte", "state": "Florida" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07540221" } ] }